Jeffrey Mosebrook Sells 1,000 Shares of Integra Lifesciences Holdings Corp (IART) Stock
Integra Lifesciences Holdings Corp (NASDAQ:IART) insider Jeffrey Mosebrook sold 1,000 shares of the business’s stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $62.42, for a total value of $62,420.00. Following the completion of the sale, the insider now directly owns 3,085 shares of the company’s stock, valued at approximately $192,565.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Integra Lifesciences stock opened at $62.88 on Friday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.27 and a current ratio of 3.52. The stock has a market capitalization of $5.32 billion, a PE ratio of 27.52, a price-to-earnings-growth ratio of 1.92 and a beta of 0.57. Integra Lifesciences Holdings Corp has a 52 week low of $41.51 and a 52 week high of $67.50.
Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings results on Wednesday, July 25th. The life sciences company reported $0.60 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.60. Integra Lifesciences had a return on equity of 17.43% and a net margin of 5.10%. The firm had revenue of $366.20 million for the quarter, compared to analyst estimates of $368.08 million. During the same period in the previous year, the company posted $0.45 earnings per share. The company’s quarterly revenue was up 29.8% compared to the same quarter last year. analysts anticipate that Integra Lifesciences Holdings Corp will post 2.4 EPS for the current year.
A number of research firms have recently commented on IART. Zacks Investment Research lowered Integra Lifesciences from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. Oppenheimer set a $70.00 price objective on Integra Lifesciences and gave the stock a “buy” rating in a research note on Tuesday, May 1st. ValuEngine upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Friday, April 27th. Cantor Fitzgerald reiterated a “hold” rating and issued a $59.00 price objective on shares of Integra Lifesciences in a research note on Wednesday, July 25th. Finally, BidaskClub lowered Integra Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 12th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $61.38.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Read More: Using the New Google Finance Tool
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.